LONDON: Aptamer Group plc (AIM: APTA), the developer of novel Optimer binders to enable innovation in the life sciences industry, today announces that its Optimer binder against cells associated with fibrotic liver disease, developed for targeted delivery of therapeutic payloads to fibrotic liver disease, has been shipped to a top 15 pharmaceutical company for evaluation…